This study proposes a deep learning-based approach using MR imaging data to identify methylation of the MGMT promoter in glioblastoma patients, which is a predictive biomarker of therapy response and prognosis, demonstrating comparable or better results than current methods with minimal parameters and incorporating an explainable AI analysis for clinical usability. This evidence concerns the gene MGMT and glioblastoma.